Lukas Leu
Lukas Leu is a portfolio manager at Bellevue, a healthcare investment specialist, known for his insights into the pharmaceutical industry. In a recent context, he criticized Novo Nordisk's communication regarding their clinical study results for the obesity medication CagriSema, highlighting the company's failure to meet expectations and provide transparent information.
Global Media Ratings
Countries Mentioned
| Country | Mentions | Sentiment | Dominance | + Persistence | x Population | = Reach | x GDP (millions) | = Power |
|---|---|---|---|---|---|---|---|---|
| Canada | 1 | 5.00 | 0.08% | +0% | 38,005,238 | 29,145 | $1,700,000 | 1,304$ |
| Totals | 1 | 38,005,238 | 29,145 | $1,700,000 | 1,304$ |
Interactive World Map
Each country's color is based on "Mentions" from the table above.
Recent Mentions
Canada:
Novo shareholder Lukas Leu, a portfolio manager at ATG Healthcare, said Novo’s cost-cutting measures fell short of reassuring investors.
5
Switzerland:
Lukas Leu criticized Novo Nordisk's communication regarding the study results.
3